Patient Compliance

A new Canadian guideline lays out the optimal strategies for providing injectable opioid agonist treatment with prescription heroin and hydromorphone for people with severe opioid use disorder.

Using gabapentinoids with opioids increases risk for opioid overdose and other severe adverse effects

The AIMS program will be fully rolled out to all 4,500+ community pharmacies later this fall

In people with diabetes, fat mass index, not body mass index (BMI), is associated with a higher risk of cardiovascular events, according to new research in CMAJ (Canadian Medical Association Journal).

Combines an integrase strand transfer inhibitor and a nucleoside reverse transcriptase inhibitor in a single-tablet once-daily regimen

In response to recent outbreaks of HIV and syphilis, a new harm reduction program in North Battleford, Saskatchewan aims to reduce the spread of disease through IV drug use.